Webinar & Meeting Reports

Thursday, May 25 at 15:30 to 17:30 CET (16:30 to 18:30 EAT; 13:30 to 15:30 GMT; 9:30 to 11:30 EDT)
The HIV epidemic continues to have a tremendous impact on global health. While we have made enormous progress in making antiretroviral therapy available to many people living with HIV, we are still not capable of eliminating infection. Consequently, people with HIV must commit to expensive, lifelong therapies; continuous monitoring; and they face drug toxicities and chronic immune activation. There is thus an urgent need to develop safe, affordable, and globally accessible curative strategies. While HIV cure research slowly becomes more mainstream in high income countries, Africa runs the risk of being left behind.

PrEP is a tool to effectively prevent HIV, but despite FDA approval in 2012, only 9 percent of Black people who could benefit from PrEP have received it. To address dismal PrEP utilization rates in the Black community, Black HIV prevention advocates convened in Atlanta, GA for the first PrEP In Black America Summit.

Tuesday, May 9 at 9:00 AM–10:30AM ET
Disparities in PrEP awareness, access, and uptake are stark in the United States, and play out along lines of race, gender, age, and geography. While we see increases in PrEP uptake overall, these metrics tend to mask the fact that the people who most need PrEP are not to be found in those numbers.

Tuesday, April 25 at 9:00 AM–10:30AM ET
Despite a dynamic research and development (R&D) pipeline for prevention products, male and female condoms remain the only multi-purpose prevention technologies (MPTs) currently available. Yet MPTs are an integral part of the HIV prevention advocacy agenda. For decades, advocates have pushed for products to be developed that simultaneously prevent HIV, other sexually transmitted infections (STIs) and/or pregnancy.